Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan (Cote d'Ivoire)

Journal de Mycologie Medicale

Volumn 24, Issue 2, 2014, Pages 93-99

  Konate A ^a,b   Yavo, W ^a   Kassi, F K ^a,c   Djohan, V ^a   Angora, E K ^a   Barro Kiki, P C ^a   Bosson Vanga, H ^a   Soro, F ^a   Menan, E I H ^a,c  

^a UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^b University Hospital of Yopougon   (Côte d’Ivoire)

^c Parasitology and Mycology Lab of Centre of diagnosis and research on AIDS and oppor dis   (Côte d’Ivoire)

Author keywords

Aetiologies; Contributing factors; Cote d'Ivoire; In vitro susceptibility; Vulvovaginal candidiasis

Indexed keywords

AMPHOTERICIN B; CHLORAMPHENICOL; CLOTRIMAZOLE; CYCLOHEXIMIDE; ECONAZOLE; FLUCYTOSINE; KETOCONAZOLE; MICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CLINICAL FEATURE; CLOTHING; COTE D'IVOIRE; CROSS-SECTIONAL STUDY; FEMALE; FUNGUS CULTURE; HOUSING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NONHUMAN; PREVALENCE; VAGINA CANDIDIASIS; VULVOVAGINITIS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RISK FACTOR;

CANDIDA ALBICANS;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; COTE D'IVOIRE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; RISK FACTORS;

EID: 84902549229     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2013.11.006     Document Type: Article

References (37)

1. Abauleth R., Boni S., Kouassi-Mbengue A., Konan J., Deza S. Étiologie et prise en charge thérapeutique des leucorrhées infectieuses au CHU de Cocody (Abidjan, CÔte d'Ivoire). Santé (Montrouge) 2006, 16:191-195.
2. Amouri I., Abbes S., Sellami H., Makni F., Sellami A., Ayadi A. La candidose vulvovaginale: revue. J Mycol Med 2010, 20:108-115.
3. Anane S., Kaouech E., Zouari B., Belhadj S., Kallel K., Chaker E. Les candidoses vulvovaginales: facteurs de risque et particularités cliniques et mycologiques. J Mycol Med 2010, 20:36-41.
4. Anis A., Asad U.K. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009, 144:68-71.
5. Bauters T.G.M., Dhont M.A., Temmerman M.I.L., Nelis H.J. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002, 187:569-574.
6. Benchellal M., Guelzim K., Lemkhente Z., Jamili H., Dehainy M., Rahali Moussaoui D., et al. La candidose vulvovaginale à l'hÔpital militaire d'instruction Mohammed V (Maroc). J Mycol Med 2011, 21:106-112.
7. Bohannon N.J.V. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 1998, 21:451-456.
8. Chassot F., Negri M.F.N., Svidzinski A.E., Donatti L., Peralta R.M., Svidzinski T.I.E., et al. Can intrauterine contraceptive devices be a Candida albicans reservoir?. Contraception 2008, 77:355-359.
9. De Leon E.M., Jacober S.J., Sobel J.D., Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infectious Dis 2002, 2:1-6.
10. Djohan V., Angora K.E., Vanga-Bosson A.H., Konaté A., Kassi F.K., Yavo W., et al. Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques à Abidjan (CÔte d'Ivoire). J Mycol Med 2012, 22:129-133.
11. Eckert L.O., Hawes E., Stevens C.E., Koutsky L.A., Eschenbach D.A., Holmes K., et al. Clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998, 92:757-765.
12. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990, 80:329-331.
13. Glover D.D., Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gynecol 2003, 11:57-160.
14. Grigoriou O., Baka S., Makrakis E., Hassiakos D., Kapparos G., Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126:121-125.
15. Guelzim K., Lmimouni B., Kouach J., El Mellouki W., El fihri H.S. Épidémiologie des candidoses vaginales à Mitrovica, Kosovo. Rev Int Serv Force Armées 2004, 77:261-266.
16. Hasna B., Houda B., Rachid S., Brahim B., Mohamed E., Nourredine D. Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques chez une population marocaine consultant à l'Institut Pasteur du Maroc. Eur J Sci Res 2012, 80:109-114.
17. Hurley R., De Louvois J. Candida vaginitis. Postgrad Med J 1979, 55:645-647.
18. Jindal N., Gill P., Aggarwal A. An epidemiological study of vulvovaginal candidiasis in women of childbearing age. Indian J Med Microbiol 2007, 25:175-176.
19. Karaer A., Boylu M., Avsar A.F. Vaginitis in Turkish women: symptoms, epidemiologic-microbiologic association. Eur J Obstet Gynecol Reprod Biol 2005, 121:211-215.
20. Kassi E.A., Assoumou A., Ouhon J., Adou-Bryn K.D., Guipie L., Koné M. Étiologies fongique et parasitaire des vulvo-vaginites à Abidjan. Med Afr Noire 1995, 42:233-235.
21. Kunzelmann V., Tietz H.J., Rossner D., Czaika V., Hopp M., Schmalreck A., et al. Prerequisites for effective therapy of chronic recurrent vaginal candidiasis. Mycoses 1996, 39:65-72.
22. Malazy O.T., Shariat M., Heshmat R., Majlesi F., Alimohammadian M., Tabari N.K., et al. Vulvovaginal candidiasis and its related factors in diabetic women. Taiwan J Obstet Gynecol 2007, 46:399-404.
23. Menan H., Ekaza E., Messou E., Adoubryn K., Yavo W., Kiki-Barro P., et al. Recherche de Candidadubliniensis chez des patients VIH+ à Abidjan (CÔte d'Ivoire). J Mycol Med 2008, 18:228-233.
24. Moreira D., Paula C.R. Vulvovaginal candidiasis. Int J Gynecol Obstet 2006, 92:266-267.
25. Nyirjesy P., Sobel J.D. Vulvovaginal candidiasis. Obstet Gynecol Clin N Am 2003, 30:671-684.
26. Powell B.L., Drutz D.J. Confirmation of corticosterone and progesterone binding activity in Candida albicans. J Infect Dis 1983, 147:359.
27. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155-2162.
28. Ringdahl E.N. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000, 61:3306-3312.
29. Rowe B.R., Logan M.N., Farrell I., Barnett A.H. Is candidiasis the true cause of vulvovaginal irritation in women with diabetes mellitus?. J Clin Pathol 1990, 43:644-645.
30. Rylander E., Berglund A.L., Krassny C., Petrini B. Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004, 80:54-57.
31. Senterre J.M., Carpentier M., Foidart J.M. Prévalence des différentes espèces de Candida au niveau vaginal dans la région Liégeoise. Rev Med Liege 2005, 60:882-884.
32. Sobel J.D. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci 1988, 544:547-557.
33. Sobel J.D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992, 14:S148-S153.
34. Sobel J.D. Vulvovaginitis due to Candida glabrata an emerging problem. Mycoses Probl 1998, 41:18-22.
35. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
36. Sobel J.D., Faro S., Force R.W., Foxman B., Ledger W.J., Nyirjesy P.R., et al. Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol 1998, 178:203-211.
37. Spinillo A., Capuzzo E., Egbe T.O., Baltaro F., Nicola S., Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995, 85:993-998.